Farrell M A, Charboneau W J, DiMarco D S, Chow G K, Zincke H, Callstrom M R, Lewis B D, Lee R A, Reading C C
Department of Radiology, Mayo Clinic, 200 First St., Rochester, MN 55902, USA.
AJR Am J Roentgenol. 2003 Jun;180(6):1509-13. doi: 10.2214/ajr.180.6.1801509.
We performed a retrospective review of imaging-guided radiofrequency ablation of solid renal tumors.
Since May 2000, 35 tumors in 20 patients have been treated with radiofrequency ablation. The size range of treated tumors was 0.9-3.6 cm (mean, 1.7 cm). Reasons for patient referrals were a prior partial or total nephrectomy (nine patients), a comorbidity excluding nephrectomy or partial nephrectomy (10 patients), or a treatment alterative to nephron-sparing surgery (one patient who refused surgery). Tumors were classified as exophytic, intraparenchymal, or central. Sixteen patients had 31 lesions that showed serial growth on CT or MR imaging. Of these 16 patients, four patients with 10 lesions had a history of renal cell carcinoma, and two patients with 11 lesions had a history of von Hippel-Lindau disease. Four patients had incidental solid masses, two of which were biopsied and shown to represent renal cell carcinoma, and the remaining two masses were presumed malignant on the basis of imaging features. Successful ablation was regarded as any lesion showing less than 10 H of contrast enhancement on CT or no qualitative evidence of enhancement after IV gadolinium contrast-enhanced MR imaging.
Of the 35 tumors, 22 were exophytic and 13 were intraparenchymal. Twenty-seven of the 35 were treated percutaneously using either sonography (n = 22) or CT (n = 5). Two patients had eight tumors treated intraoperatively using sonography. Patients were followed up with contrast-enhanced CT (n = 18), MR imaging (n = 5), or both (n = 5) with a follow-up range of 1-23 months (mean, 9 months). No residual or recurrent tumor and no major side effects were seen.
Preliminary results with radiofrequency ablation of exophytic and intraparenchymal renal tumors are promising. Radiofrequency ablation is not associated with significant side effects. Further follow-up is necessary to determine the long-term efficacy of radiofrequency ablation.
我们对影像引导下实体肾肿瘤的射频消融进行了回顾性研究。
自2000年5月以来,对20例患者的35个肿瘤进行了射频消融治疗。治疗肿瘤的大小范围为0.9 - 3.6厘米(平均1.7厘米)。患者转诊的原因包括既往接受过部分或全肾切除术(9例)、存在排除肾切除术或部分肾切除术的合并症(10例),或作为保留肾单位手术的替代治疗方法(1例拒绝手术的患者)。肿瘤分为外生性、实质内型或中央型。16例患者的31个病灶在CT或MR成像上显示有连续生长。在这16例患者中,4例患者的10个病灶有肾细胞癌病史,2例患者的11个病灶有冯·希佩尔-林道病病史。4例患者有偶然发现的实性肿块,其中2例经活检显示为肾细胞癌,其余2个肿块根据影像学特征推测为恶性。成功消融被定义为任何在CT上显示对比增强小于10 H或静脉注射钆对比增强MR成像后无增强定性证据的病灶。
35个肿瘤中,22个为外生性,13个为实质内型。35个肿瘤中有27个通过超声(n = 22)或CT(n = 5)经皮治疗。2例患者的8个肿瘤通过术中超声治疗。对患者进行了对比增强CT(n = 18)、MR成像(n = 5)或两者(n = 5)随访,随访时间为1 - 23个月(平均9个月)。未发现残留或复发性肿瘤,也未出现重大副作用。
外生性和实质内型肾肿瘤射频消融的初步结果令人鼓舞。射频消融无明显副作用。需要进一步随访以确定射频消融的长期疗效。